Congress Explores Remedies For Corporate Tax Inversion “Fever”
This article was originally published in The Rose Sheet
Senate Finance Committee Chairman Wyden questions the suggestion that drug manufacturers’ corporate tax inversions lead to lower health-care costs in the U.S. Inversion transactions have been on the rise since Helen of Troy’s landmark reorganization in the early 1990s in Bermuda, with President Obama recently casting firms that move their businesses overseas for tax benefits as “corporate deserters.”
You may also be interested in...
OTC private label leader Perrigo acquires Irish firm Elan for $8.6 billion in a deal that will bring tax savings from being incorporated in Ireland, provide a stage for European expansion and tap into Elan’s royalty rights. “Simply stated, we're going to be able to further our international platform,” CEO Joseph Papa says.
It's not clear that the proposed revisions and additions to the Centers for Medicare and Medicaid Services’ existing coverage with evidence development study design requirements would address what some experts view as a program failure – the fact that sponsors of the vast majority of technologies subject to CED have not generated the data CMS is looking for.
But premiums in future years made need to keep pace with accelerating Medicare spending on Alzheimer’s drugs.